참고문헌 (24)

1. N Engl J Med Ziegler EJ 429 324 1991 10.1056/NEJM199102143240701 

   상세보기

2. US Food and Drug Administration. Transcripts of the open meeting of the vaccines and related biological products advisory-comments of J.P. Siegel. FDA: Bethesda, MD, 4 September 1991. 

3. N Engl J Med Warren HS 1153 326 1992 10.1056/NEJM199204233261711 

   상세보기

4. N Engl J Med Siegel JP 890 327 1992 

5. N Engl J Med Rosenfeld S 889 327 1992 10.1056/NEJM199209173271214 

   상세보기

6. Ann Intern Med McCloskey RV 1 121 1994 10.7326/0003-4819-121-1-199407010-00001 

   상세보기

7. Lancet Gruppo 397 1 1986 

8. Lancet ISIS-2 Collaborative Group 349 2 1988 

9. Wilcox, R.G., Olsson, C.G., Skene, A.M., Von Der Lippe, G., Jensen, G., Hampton, J.R., For The Asset Study Group. TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION - Anglo-Scandinavian Study of Early Thrombolysis (ASSET). The Lancet, vol.332, no.8610, 525-530.

   상세보기

10. N Engl J Med ISAM (Intravenous Streptokinase in Acute Myocardial Infarction) Study Group 1465 314 1986 10.1056/NEJM198606053142301 

    상세보기

11. Lancet AIMS (APSAC Intervention Mortality Study) Trial Study Group 545 1 1988 

12. Blackwelder, W.C.. ''Proving the null hypothesis'' in clinical trials. Controlled clinical trials, vol.3, no.4, 345-353.

    상세보기

13. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guidelines. Choice of control group in clinical trials. July 2000. Available at http://www.ifpma.org/pdfifpma/e10step4.pdf 

14. Siegel, Jay P.. Equivalence and noninferiority trials. The American heart journal, vol.139, no.4, S166-S170.

    상세보기

15. Van de Werf, Frans. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. The Lancet, vol.354, no.9180, 716-722.

    상세보기

16. Lancet Fibrinolytic Therapy Trialists Collaborative Group 311 343 1994 10.1016/S0140-6736(94)91161-4 

    상세보기

17. US Food and Drug Administration. Letter to Institute for Human Gene Therapy, University of Pennsylvania, 3 March 2000. Available at http://www.fda.gov/foi/warning_letters/m3435n.pdf 

18. Fed Regist International Conference 25691 62 1997 

19. US Department of Health and Human Services. New initiatives to protect participants in gene therapy trials. HHS News, 7 March 2000. Available at http://www.fda.gov/bbs/topics/NEWS/NEW00717.html 

20. US Food and Drug Administration. Letter from JP Siegel, Center for Biologics Evaluation and Research, to sponsors of an IND or master file using or producing a gene therapy product. 6 March 2000. Available at http://www.fda.gov/cber/ltr/gt030600.pdf 

21. US Food and Drug Administration. Transcripts of the meeting of the Biological Response Modifiers Advisory Committee: discussion of the 6 March 2000 FDA gene therapy letter: preclinical and clinical issues. 5 April 2001. Available at http://www.fda.gov/ohrms/dockets/ac/01/briefing/3739b1_05.pdf 

22. US Food and Drug Administration. Transcripts of the meeting of the Biological Response Modifiers Advisory Committee: overview of gene therapy surveillance inspections. Salewski JP, Bioresearch Monitoring Branch, CBER. 5 April 2001. Available at http://www.fda.gov/ohrms/dockets/ac/01/briefing/3739b1_02_salewskislides.ppt 

23. Shalala, Donna. Protecting Research Subjects - What Must Be Done. The New England journal of medicine, vol.343, no.11, 808-810.

    상세보기

24. Morse, M A, Califf, R M, Sugarman, J. Monitoring and ensuring safety during clinical research.. JAMA : the journal of the American Medical Association, vol.285, no.9, 1201-1205.

    상세보기